Ptc Therapeutics (PTCT) Receivables - Other (2023 - 2024)

Ptc Therapeutics' (PTCT) quarterly Receivables - Other came in at $800000.0 in Q1 2024, up 300.0% quarter-over-quarter from $200000.0 in Q4 2023.

Ptc Therapeutics (PTCT) Receivables - Other (2023 - 2024) Analysis & Trends

Ptc Therapeutics' Receivables - Other history runs 2 years deep, the most recent figure standing at $800000.0 for Q1 2024.

On a quarterly basis, Receivables - Other changed N/A year-over-year to $800000.0 in Q1 2024; TTM through Mar 2024 was $800000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $200000.0, changed N/A from the prior year.
Receivables - Other grew to $800000.0 in Q1 2024 per PTCT's latest filing, from $200000.0 in the prior quarter.
Across five years, Receivables - Other topped out at $1.4 million in Q3 2023 and bottomed at $200000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Ptc Therapeutics	6.47 Bn	4.58 Bn	244.52 Mn

Download Data